Mirtazapine Sandoz (Mirtazapine)

Mirtazapine works by blocking central presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2, 5‑HT3 and H1 receptors. This combined action enhances serotonergic and noradrenergic neurotransmission while providing sedative effects that contribute to its antidepressant activity.

The appropriate dose of Mirtazapine Sandoz is determined by the prescribing clinician based on the individual’s clinical response, age, weight and comorbid conditions. The prescriber will start with a low dose and may adjust it gradually to achieve optimal therapeutic effect.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct mechanism that includes antihistaminic activity, leading to greater sedation and appetite stimulation. It may be preferred when patients experience insomnia or weight loss, whereas SSRIs are generally less sedating and have a different side‑effect profile.

Mirtazapine Sandoz tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally as a tablet, usually once daily in the evening. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to achieve consistent absorption.

Serious risks include agranulocytosis or severe neutropenia, which require immediate medical attention, emergence or worsening of suicidal thoughts especially early in treatment, severe hypersensitivity reactions such as rash or angioedema, and rare hepatic dysfunction.

Mirtazapine should be avoided in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, individuals with severe hepatic impairment, and patients with a history of severe agranulocytosis. Clinicians must also assess risk in patients with uncontrolled cardiovascular disease.